More seizure-free days may be on the horizon
The EMERALD clinical study is evaluating an investigational medicine, relutrigine, to understand its safety and how effective it may be at reducing seizures in children and adults living with Developmental and Epileptic Encephalopathies (DEEs).
Relutrigine is an investigational medicine that can be taken by mouth or administered through a G/J tube. It is designed to modulate sodium flow in brain cells by targeting overactive sodium channels associated with seizure activity—aiming to improve seizure control while minimizing effects on normal brain function.
- Available across all study regions
- Sites are located across the United States, South America, Europe, and Australia.
Additional Information:
Visit the EMERALD Study Website
The information here is not intended to provide diagnosis, treatment, or medical advice and should not be considered a substitute for advice from a healthcare professional. The content provided is for informational purposes only. LGS Foundation is not responsible for actions taken based on the information included on this webpage. Please consult with a physician or other healthcare professional regarding any medical or health-related diagnosis or treatment options.
Updated 08/27/25 (KK)